WEHI 164 subclone 13 assay for TNF: sensitivity, specificity, and reliability - PubMed (original) (raw)
WEHI 164 subclone 13 assay for TNF: sensitivity, specificity, and reliability
M K Eskandari et al. Immunol Invest. 1990 Feb.
Abstract
Tumor necrosis factor alpha (TNF) is a peptide monokine involved in a number of immune reactions. To further understand the role of TNF in disease states it is critical to have an inexpensive, yet sensitive and specific assay. Additionally, the effects of prostaglandin E2 (PGE2), dexamethasone (dex), and cyclosporine A (CsA) on TNF gene expression have been studied, although little is known of the effects these compounds have on TNF containing samples. The aim of this study is to determine the sensitivity and specificity of a highly sensitive cell line to the actions of TNF, and to elucidate parameters which affect the stability of TNF in biological fluids. Dex and PGE2 at concentrations of 10(-5), 10(-7), and 10(-9) M, were shown not to effect the WEHI assay, and neither did CsA (10 ng/ml-1 ug/ml). The cells were not lysed by recombinant murine IL-1 alpha or beta, human recombinant IL-1 alpha or beta, human recombinant IL-2 or human recombinant IL-6 at concentrations ranging from 0.02 pg/ml to 1.0 ug/ml, or murine gamma-IFN from 100 pg/ml to 10 ng/ml. TNF containing samples with 1%-10% fetal calf serum maintained their cytolytic activity even after three freeze-thaw cycles. Serum samples did not lose any cytolytic activity with up to 11 cycles of freezing and thawing whereas, tissue culture media, containing TNF, lost significant activity with freeze-thawing. The WEHI assay has successfully detected cytolytic activity from lipopolysaccharide stimulated specimens from a number of different species. These data show the utility of this highly sensitive and specific assay. Furthermore, the WEHI assay showed a high degree of reproducibility in repeated assays.
Similar articles
- Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT, Palladino MA Jr, Jaffe HS, Espevik TP, Rayner AA. Gemlo BT, et al. Cancer Res. 1988 Oct 15;48(20):5864-7. Cancer Res. 1988. PMID: 3139285 Clinical Trial. - Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
Nishihara K, Barth RF, Wilkie N, Lang JC, Oda Y, Kikuchi H, Everson MP, Lotze MT. Nishihara K, et al. Cancer Gene Ther. 1995 Jun;2(2):113-24. Cancer Gene Ther. 1995. PMID: 7621259
Cited by
- Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain.
Bloomingdale P, Meregalli C, Pollard K, Canta A, Chiorazzi A, Fumagalli G, Monza L, Pozzi E, Alberti P, Ballarini E, Oggioni N, Carlson L, Liu W, Ghandili M, Ignatowski TA, Lee KP, Moore MJ, Cavaletti G, Mager DE. Bloomingdale P, et al. Front Pharmacol. 2022 Jan 19;12:817236. doi: 10.3389/fphar.2021.817236. eCollection 2021. Front Pharmacol. 2022. PMID: 35126148 Free PMC article. - Innate Immune Functions of Astrocytes are Dependent Upon Tumor Necrosis Factor-Alpha.
Rodgers KR, Lin Y, Langan TJ, Iwakura Y, Chou RC. Rodgers KR, et al. Sci Rep. 2020 Apr 27;10(1):7047. doi: 10.1038/s41598-020-63766-2. Sci Rep. 2020. PMID: 32341377 Free PMC article. - Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method.
Tierrablanca-Sánchez L, Pérez Medina Martínez V, Ramírez Ibañez ND, Pérez Ramírez NO, Flores Ortiz FL, Medina-Rivero E. Tierrablanca-Sánchez L, et al. J Vis Exp. 2017 Sep 16;(127):55376. doi: 10.3791/55376. J Vis Exp. 2017. PMID: 28994757 Free PMC article. - Increasing TNF levels solely in the rat hippocampus produces persistent pain-like symptoms.
Martuscello RT, Spengler RN, Bonoiu AC, Davidson BA, Helinski J, Ding H, Mahajan S, Kumar R, Bergey EJ, Knight PR, Prasad PN, Ignatowski TA. Martuscello RT, et al. Pain. 2012 Sep;153(9):1871-1882. doi: 10.1016/j.pain.2012.05.028. Epub 2012 Jul 4. Pain. 2012. PMID: 22770843 Free PMC article. - Improvement of a cytokine (TNF-α) bioassay by serum-free target cell (WEHI 164) cultivation.
Figenschau Y, Sveinbjörnsson B, Bertheussen K. Figenschau Y, et al. Cytotechnology. 1999 Mar;29(2):121-34. doi: 10.1023/A:1008052307547. Cytotechnology. 1999. PMID: 22359061 Free PMC article.